Robust catheter tubing

Information

  • Patent Grant
  • 9539368
  • Patent Number
    9,539,368
  • Date Filed
    Wednesday, June 8, 2016
    8 years ago
  • Date Issued
    Tuesday, January 10, 2017
    8 years ago
Abstract
Elongate, flexible catheter includes a shaft having a proximal end, a distal end, and a lumen extending therein. The shaft has an inner layer comprising an amorphous polyamide having a Shore D durometer value of greater than 78, and an outer layer comprising a semi-crystalline polyamide or copolyamide having a Shore D durometer value of less than 76. The outer layer is thinner than the inner layer. The shaft has an increased resistance to kinking as compared to a similar shaft of a single layer of the amorphous polyamide having a Shore D durometer value of greater than 78.
Description
BACKGROUND

The invention relates to the field of intravascular catheters, and more particularly to a balloon catheter or other catheter components, such as a guidewire enclosure and catheter tubing, that would benefit from the properties of the materials disclosed herein.


In percutaneous transluminal coronary angioplasty (PTCA) procedures, a guiding catheter is advanced until the distal tip of the guiding catheter is seated in the ostium of a desired coronary artery. A guidewire, positioned within an inner lumen of an dilatation catheter, is first advanced out of the distal end of the guiding catheter into the patient's coronary artery until the distal end of the guidewire crosses a lesion to be dilated. Then the dilatation catheter having an inflatable balloon on the distal portion thereof is advanced into the patient's coronary anatomy, over the previously introduced guidewire, until the balloon of the dilatation catheter is properly positioned across the lesion. Once properly positioned, the dilatation balloon is inflated with liquid one or more times to a predetermined size at relatively high pressures (e.g. greater than 8 atmospheres) so that the stenosis is compressed against the arterial wall and the wall expanded to open up the passageway. Generally, the inflated diameter of the balloon is approximately the same diameter as the native diameter of the body lumen being dilated so as to complete the dilatation but not overexpand the artery wall. The rate of expansion of the balloon for a given pressure is an important consideration in the design of the dilation catheter, as greater than anticipated expansion of the balloon against the vessel wall can cause trauma to the vessel wall. After the balloon is finally deflated, blood flow resumes through the dilated artery and the dilatation catheter can be removed from the patient's artery.


In such angioplasty procedures, there may be restenosis of the artery, i.e. reformation of the arterial blockage, which necessitates either another angioplasty procedure, or some other method of repairing or strengthening the dilated area. To reduce the restenosis rate and to strengthen the dilated area, physicians frequently implant an intravascular prosthesis, generally called a stent, inside the artery at the site of the lesion. Stents may also be used to repair vessels having an intimal flap or dissection or to generally strengthen a weakened section of a vessel. Stents are usually delivered to a desired location within a coronary artery in a contracted condition on a balloon of a catheter which is similar in many respects to a balloon angioplasty catheter, and expanded to a larger diameter by expansion of the balloon. The balloon is deflated to remove the catheter and the stent left in place within the artery at the site of the dilated lesion.


In the design of catheter balloons and catheter tubing, material characteristics such as strength, flexibility and compliance must be tailored to provide optimal performance for a particular application. Angioplasty balloons and catheter tubing preferably have high strength for inflation at relatively high pressure, and high flexibility and softness for improved ability to track the tortuous anatomy. The balloon compliance, for example, is chosen so that the balloon will have a desired amount of expansion during inflation. Compliant balloons, for example balloons made from materials such as polyethylene, exhibit substantial stretching upon the application of tensile force. Noncompliant balloons, for example balloons made from materials such as PET, exhibit relatively little stretching during inflation, and therefore provide controlled radial growth in response to an increase in inflation pressure within the working pressure range. However, noncompliant balloons generally have relatively low flexibility and softness, making it more difficult to maneuver through various body lumens. Heretofore the art has lacked an optimum combination of strength, flexibility, and compliance, and particularly a low to non-compliant balloon with high flexibility and softness for enhanced trackability. Semi-compliant balloons made from semi-crystalline nylon 11, nylon 12, and copolymers of these nylons, such as poly ether block amide (for example, Pebax from Arkema) address these shortcomings and provide low distensibility and good flexibility, thus being used in many balloon dilatation catheters and stem delivery system.


For ease of thermal bonding to afore mentioned semi-compliant balloons, it is also preferred that the shaft of the balloon dilatation catheters and stent delivery system are also derived from same materials. Many balloon dilatation catheters and stent delivery systems therefore use shafts derived from these materials. The relative hardness and flexibility of the catheter tubing is also a constant compromise between the need for an agile tubing that can navigate the various body lumens, while having enough stiffness to be able to be pushed from a proximal end outside the body through the patient's vascular tract. A tubing that is relatively stiff will transmit proximal force more efficiently to the distal end, giving the practitioner more control over the location and position of the catheter balloon. However, stiffer tubing makes it much more difficult to bend or track curvatures in the body, leading to the paradox of the need for stiffer yet more flexible tubing. Moreover, stiffer materials when used to make catheter shafts have a higher tendency to kink, making it more difficult to control or push. Therefore, it is desirable to be able to increase stiffness and thus pushability by incorporating nylons having higher stiffness than semi-crystalline nylons having been used thus far. Some amorphous nylons offer desired higher stiffness than semi-crystalline nylons. However, the higher stiffness amorphous nylons are more susceptible to damage from solvents, such as isopropyl alcohol, used in the manufacturing, cleaning processes, and during clinical use. The present invention is directed to address this issue.


SUMMARY OF THE INVENTION

The softness and flexibility of a balloon or catheter tubing is a function of the flexural modulus of the polymeric material of the balloon, so that a balloon or tubing material having a higher Shore D durometer hardness, which yields a stronger and stiffer balloon or catheter tubing, has a higher flexural modulus. Conversely, a balloon or catheter tubing material having a lower Shore D durometer hardness, which thus provides a soft and flexible balloon or tubing, has a lower flexural modulus. The present invention is directed to a catheter tubing formed with a combination of at least two polyamides, a high durometer hardness material and a lower durometer hardness material.


The tubing can be made from a blend of the two polyamides, or a co-extrusion of the two polyamides with an inner layer and an outer layer. The first inner polyamide has a Shore D durometer hardness of greater than 78 D, more preferably Shore D durometer hardness of greater than 80 D, and can be preferably selected from various transparent amorphous nylons having segment such as an aliphatic segment, an aromatic segment, or a cycloaliphatic segment. The second outer polyamide has a lower durometer hardness than the first polyamide, and preferably less than 76 D, and preferably a block copolymer of nylon and polytetramethylene oxide (i.e. a copolyamide), or Pebax. The second outer polyamide is preferably semi-crystalline polyamide, thus providing enhanced resistance to solvents, such as isopropyl alcohol, used in the manufacturing, cleaning processes, and during clinical use. Both inner and outer polyamides preferably have the same amide block or segment, e.g. nylon 12, nylon 11, or nylon 6,6.


The preferred high hardness material is a nylon referred to as transparent amorphous nylon. The transparent amorphous nylon preferably has either an aliphatic segment, an aromatic segment, or a cycloaliphatic segment.


The catheter tubing of the invention may be formed by coextruding a tubular product formed from the two polymeric components to create a tubing having an outer layer and an inner layer of the two materials.


Various designs for balloon catheters well known in the art may be used in the catheter system of the invention. For example, conventional over-the-wire balloon catheters for angioplasty or stent delivery usually include a guidewire receiving lumen extending the length of the catheter shaft from a guidewire port in the proximal end of the shaft. Rapid exchange balloon catheters for similar procedures generally include a short guidewire lumen extending to the distal end of the shaft from a guidewire port located distal to the proximal end of the shaft.


In the case of a robust co-extruded catheter shaft, an inner layer can be comprised of a high modulus or high Shore D durometer nylon, preferably a Shore D durometer value greater than 80, such as Grilamid TR55 LX nylon 12 from EMS-American Grilon Inc., which provides a high modulus for enhanced pushability. Also, it would be beneficial if the glass transition temperature of the high modulus polymer forming the inner layer is greater than 100° C., and more preferably greater than 120° C. However, the TR55 LX or other high modulus amorphous nylon has a greater tendency to kink and is susceptible to attack by solvents. To combat the kink propensity and to protect the catheter shaft from solvents, a thin outer layer of lower modulus material such as Pebax is formed over the TR55 LX inner layer to serve as a protective layer and to resist kinking of the shaft. The outer layer can be selected from semi-crystalline polyamide or more preferably from a copolyamide of lower durometer value such as Pebax 72 D, Pebax 63 D, and the like, where the Shore D durometer value is less than 76.


By incorporating an amorphous polyamide such as TR 55 LX as one layer, the dimensional stability is increased for as the shelf life of the catheter increases due to the higher glass transition temperature, as compared with nylon 12 or Pebax which has a glass transition temperature at or below 55° C. Also, a higher tensile strength (approximately 11,000 psi) of amorphous nylon TR 55 LX compared with nylon 12 or Pebax (7,500-8,200) provides a higher rupture limit with the same wall thickness.


The co-axial tubing can be formed into a tapered configuration, where the radius of the shaft gradually reduces until the balloon attachment point. This gradual reduction in the radial component of the shaft serves to eliminate the mid-shaft portion of the catheter, which simplifies the manufacturing process by avoiding a laser operation or other mechanism to attach the mid-shaft.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is an elevated view partially in section of a balloon catheter which embodies features of the invention, showing the balloon in an expanded state;



FIG. 2 is a transverse cross sectional view of the balloon catheter of FIG. 1 taken along lines 2-2;



FIG. 3 is a transverse cross sectional view of the balloon catheter of FIG. 1 taken along lines 3-3;



FIG. 4 is a graph of the compliance of the catheter balloon using a first preferred blend of materials;



FIG. 5 is a cross-sectional view of a catheter shaft with an inner layer, an intermediate layer, and an outer layer;



FIG. 6 is an enlarged, partially cut-away view of a catheter shaft illustrating multiple layers, including an embedded high strength ribbon or coil in the outer layer; and



FIG. 7 is an enlarged, cross-sectional view of another embodiment of a catheter shaft.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

In angioplasty balloons, an object is to apply a high pressure to the interior wall of the lumen to compress the plaque and/or to fully expand the stent. This relies on a robust balloon with a sturdy out wall and a high pressure capability. The compliance of the balloon, i.e., the expansion of the balloon as a function of internal pressure, is preferably low or flat to more accurately control the amount of pressure applied to the arterial wall. However, the deliverability of the balloon is also a factor, especially where tortuous body lumens are involved. Stiff balloons (i.e., high modulus materials) tend to have poor flexibility and lack the maneuverability to navigate the various body lumens, and thus make poor choices for catheter balloons. Conversely, flexible balloons (low modulus materials) that have high compliance are poorly suited to apply a precise known pressure on the arterial wall due to a high expansion rate per applied pressure. The goal is thus to increase the rupture strength by adding the high modulus material such as nylon to the softer polyamide material.


Soft polyamide materials such as Pebax™ are semi-crystalline polymers and usually include an amorphous segment. The amorphous segment has a lower density than the crystalline structure and thus is weaker in general than crystalline segments. If the amorphous segment can be reinforced by adding a small amount of a higher modulus material the response of the amorphous segment can be delayed and the overall strength of the material can be strengthened. The high modulus material preferably has a Shore D durometer hardness of 78 D or more. Suitable materials include transparent amorphous nylon such as nylon 12, and more preferably a nylon 12 with a aliphatic segment, an aromatic segment, or a cycloaliphatic segment. These nylons are transparent amorphous because they are essentially amorphous, lacking the crystalline structure of other more conventional nylon 12. The aliphatic segment, aromatic segment, or cycloaliphatic segment does not crystallize with the main chain, disrupting the formation of longer crystalline chains in the polymer. The amorphous segment of the transparent amorphous nylon 12 combines with the amorphous segment of the Pebax to strengthen the Pebax by enhancing the weakest link in the chain, thereby increasing the overall strength of the polymer.



FIG. 1 illustrates a balloon catheter which embodies features of the invention. The catheter 10 of the invention generally comprises an elongated catheter shaft 11 having a proximal section, 12 a distal section 13, an inflatable balloon 14 formed of a blend of polymeric materials on the distal section 13 of the catheter shaft 11, and an adapter 17 mounted on the proximal section 12 of shaft 11. In FIG. 1, the catheter 10 is illustrated within a patient's body lumen 18, prior to expansion of the balloon 14.


In the embodiment illustrated in FIG. 1, the catheter shaft 11 has an outer tubular member 19 and an inner tubular member 20 disposed within the outer tubular member and defining, with the outer tubular member, inflation lumen 21. Inflation lumen 21 is in fluid communication with the interior chamber 15 of the inflatable balloon 14. The inner tubular member 20 has an inner lumen 22 extending therein which is configured to slidably receive a guidewire 23 suitable for advancement through a patient's coronary arteries. The distal extremity of the inflatable balloon 14 is sealingly secured to the distal extremity of the inner tubular member 20 and the proximal extremity of the balloon is sealingly secured to the distal extremity of the outer tubular member 19.



FIGS. 2 and 3 show transverse cross sections of the catheter shaft 11 and balloon 14, respectively, illustrating the guidewire receiving lumen 22 of the guidewire's inner tubular member 20 and inflation lumen 21 leading to the balloon interior 15. The balloon 14 can be inflated by radiopaque fluid introduced at the port in the side arm 24 into inflation lumen 21 contained in the catheter shaft 11, or by other means, such as from a passageway formed between the outside of the catheter shaft and the member forming the balloon, depending on the particular design of the catheter. The details and mechanics of balloon inflation vary according to the specific design of the catheter, and are well known in the art.


Non-compliant or low-compliant balloon 14 and/or the shaft 11 is formed of a blend of a first polyamide having a Shore D durometer hardness greater than 78 D and a copolyamide of lower durometer hardness, preferably less than 76 D. A preferred polyamide having a Shore D durometer hardness greater than 78 D is an amorphous polyamide such as EMS TR 55 (transparent amorphous nylon 12), Arkema Rilsan G110 (transparent amorphous nylon 12), or Cristamid MS 110 (transparent amorphous nylon 12). The polyamide is preferably includes a cycloaliphatic segment, an aromatic segment, or an aliphatic segment. Such polyamides are also referred to as transparent polyamide. The preferred copolyamide material for forming the polymeric blend for the balloon is Pebax, and more preferably Pebax 72 D, Pebax 70 D, Pebax 63 D, or Pebax 55 D. Alternatively, the copolyamide of lower durometer hardness is preferably a block copolymer of nylon 12 and polytetramethylene oxide.


The flexural modulus of the polyamide is preferably greater than 1700 MPa (240,000 psi) and the flexural modulus of the copolyamide is less than 850 MPa (120,000 psi). The tensile strength at break of both polyamides is at least 50 MPa, and elongation at break of both polyamides is at least 150%.


The catheter shaft will generally have the dimensions of conventional dilatation or stent deploying catheters. The length of the catheter 10 may be about 90 cm to about 150 cm, and is typically about 135 cm. The outer tubular member 19 has a length of about 25 cm to about 40 cm, an outer diameter (OD) of about 0.039 in to about 0.042 in, and an inner diameter (ID) of about 0.032 in. The inner tubular member 20 has a length of about 25 cm to about 40 cm, an OD of about 0.024 in and an ID of about 0.018 in. The inner and outer tubular members may taper in the distal section to a smaller OD or ID.


The length of the compliant balloon 14 may be about 1 cm to about 4 cm, preferably about 0.8 cm to about 4.0 cm, and is typically about 2.0 cm. In an expanded state, at nominal pressure of about 8 to about 10 atm, the balloon diameter is generally about 0.06 in (1.5 mm) to about 0.20 in (5.0 mm). and the wall thickness is about 0.0006 in (0.015 mm) to about 0.001 in (0.025 mm), or a dual wall thickness of about 0.025 mm to about 0.056 mm. The burst pressure is typically about 20 to 26 atm, and the rated burst pressure is typically about 18 atm.


In a presently preferred embodiment, the balloon 14 may include wings, which may be folded into a low profile configuration (not shown) for introduction into and advancement within the patient's vasculature. When inflating the balloon to dilate a stenosis, the catheter 10 is inserted into a patient's vasculature to the desired location, and inflation fluid is delivered through the inflation lumen 21 to the balloon 14 through the inflation port 24. The semi-compliant or noncompliant balloon 14 expands in a controlled fashion with limited radial expansion, to increase the size of the passageway through the stenosed region. Similarly, the balloon has low axial growth during inflation, to a rated burst pressure of about 14 atm, of about 5 to about 10%. The balloon is then deflated to allow the catheter to be withdrawn. The balloon may be used to deliver a stent (not shown), which may be any of a variety of stent materials and forms designed to be implanted by an expanding member, see for example U.S. Pat. No. 5,514,154 (Lau et al.) and U.S. Pat. No. 5,443,500 (Sigwart), incorporated herein in their entireties by reference.


Example 1

A proximal shaft for the over-the-wire catheter may have a tapered tubing coextruded and tapered with TR55 inner layer and Pebax 72 D outer layer. The proximal wall thickness of TR55 may be approximately 0.005″ and a proximal wall thickness of Pebax 72 D may be approximately 0.001″. A distal wall thickness of TR55 is approximately 0.002″ and a distal wall thickness of Pebax 72 D is approximately 0.001″. In addition to balloons, the blended composition has usefulness as other parts of the catheter, such as the guidewire enclosure 20 of FIGS. 1-3. The inner member of the multi-layered tubing can have a lubricious inner layer (HDPE, UHMWPE, and the like) with bonding mid layer and polymer blend outer layer. Like the catheter balloon, the blend is comprised of one polymer having a Shore D durometer greater than 78 and another polymer having lower durometer, preferably less than 76 D. Both polyamides preferably have same amide block or segment, i.e. one type of amide (nylon) block, solely comprised of nylon 12, nylon 11, nylon 6, or nylon 6, 6 but not combination of these.


The polyamide having Shore D durometer greater than 78 D is preferably amorphous polyamide selected from polyamide such as EMS TR 55 (transparent amorphous nylon 12), Arkema Rilsan G110 (transparent amorphous nylon 12), or Cristamid MS 110 (transparent amorphous nylon 12). This polyamide is preferably a copolyamide comprising cycloaliphatic, and/or aromatic, and/or aliphatic segment. The other copolyamide of lower durometer is preferably a block copolymer of nylon 12 and polytetramethylene oxide, such as Pebax 72 D, Pebax 70 D or Pebax 63 D.


The high durometer polymer serves to increase resistance to collapse of the tubing and provides enhanced pushability while the lower durometer polymer provides flexibility and kink resistance. Although it is preferred to have blends of high miscibility, the blend ratio is such that the lower durometer polymer forms a “virtual” continuous phase while the higher durometer polymer forms “virtual” reinforcement.


As shown in FIG. 5, an outer layer 60 of the catheter shaft can be comprised of an amorphous polyamide selected from polyamide such as EMS TR 55 (transparent amorphous nylon 12), Arkema Rilsan G110 (transparent amorphous nylon 12), Cristamid MS 110 (transparent amorphous nylon 12), polyamide 11, polyamide 6, or polyamide 6,6. This polyamide is preferably a copolyamide comprising cycloaliphatic, and/or aromatic, and/or aliphatic segment. In one embodiment, the outer layer 60 is blended with a softer polyamide such as a crystalline or semi-crystalline copolymer of nylon 12 and polytetramethylene oxide or polytetramethylene glycol, e.g. Pebax 72 D or Pebax 70 D. This blending offers a higher strength outer layer that offers higher pushability and resists collapse, while the copolymer operates to resist kinking and yield greater flexibility. Although it is preferable to have blends of high miscibility, blend ratios are such that the lower durometer polymer forms a virtual continuous phase and the high durometer polymer forms a virtual reinforcement. The intermediate layer 70 is a bonding layer, such as Primacor, to meld the inner and outer layers together. The inner layer 80 can be a lubricious material that reduces the friction of a guide wire passing through the lumen 90, such as HDPE or UHMWPE. Other materials are also contemplated, as long as the outer layer has a glass transition or melting temperature that is preferably lower than, or at least approximately equal to, the surface temperature of the mold during the blowing or forming process of the balloon.



FIG. 6 shows another embodiment of a catheter shaft 120 having a lumen 125 extending therein, the shaft 120 having an inner layer 130 comprising a low friction material such as high density polyethylene and an intermediate layer 140 serving as a bonding layer. An outer layer comprising a first polymer having a first Shore D durometer value of no greater than 76 D, such as Pebax 72 D or Pebax 63 D is impregnated with a second polymer having a Shore D durometer value that is greater than the first Shore D durometer value, and preferably greater than 78 such as TR55 or the other transparent nylon 12 materials discussed above. The second polymer 160 can be wrapped around the shaft 120 like a helix or coil to reinforce the outer layer 150.



FIG. 7 illustrates another embodiment of a catheter shaft having an inner layer 220 of a high modulus material with a high Shore D durometer value such as amorphous nylon 12. This inner layer material provides a high strength catheter shaft for higher pushability. However, the transparent nylon 12 has a tendency to kink, and it is susceptible to solvents used in cleaning or other manufacturing processes. To resist kinking, and to protect the catheter from solvents, a thin outer layer 240 of Pebax or other soft copolyamide is formed over the inner layer 220. The two layers 220, 240 can be co-extruded in a single operation to create the shaft 200 of FIG. 7. The shaft 220 also incorporates a tapered section 250 as the shaft transitions from a main body portion to the portion 260 to the portion 270 where a balloon may be attached. In existing catheter shafts, this section requires a mid shaft section that must be separately attached to the catheter shaft using expensive laser equipment. The tapered transition from the main body portion 260 to the balloon attachment portion 270 eliminates the need for a mid shaft and thus the need for the laser equipment and assembly line personnel required to operate the laser equipment, resulting in a more efficient and cost effective catheter.


The shaft of FIG. 7 preferably has both co-extruded layers 220, 240 with a common amide block or segment for better adhesion or compatibility, i.e., one type of amide (nylon) block, comprising one and only one of nylon 12, nylon 11, nylon 6, or nylon 6,6. The inner polymer is preferably a polyamide having a Shore D durometer value of greater than 78, such as amorphous polyamide selected from EMS TR55, Arkema Rilsan G110, or Cristamid MS 110, all commonly referred to as transparent nylon 12. This polyamide preferably comprises cycloaliphatic, aromatic, and/or aliphatic segments. The outer layer 240 may preferably be a copolyamide block copolymer of nylon 12 and polytetramethylene glycol.


Various embodiments are described above in effort to illustrate the concepts of the present invention, but these embodiments are not intended to be limiting or exclusive. Rather, the scope of the invention is to be determined by the words of the appended claims, interpreted in the context of the above description but not limited to those examples and embodiments described above and shown in the Figures.

Claims
  • 1. An elongate, flexible catheter, comprising: a shaft having a proximal end, a distal end, and a lumen extending therein, the shaft having an inner layer comprising an amorphous polyamide having a Shore D durometer value of greater than 78, and an outer layer comprising a semi-crystalline polyamide or copolyamide having a Shore D durometer value of less than 76, wherein the outer layer is thinner than the inner layer, the shaft having an increased resistance to kinking as compared to a similar shaft of a single layer of the amorphous polyamide having a Shore D durometer value of greater than 78.
  • 2. The elongate, flexible catheter of claim 1 wherein the amorphous polyamide of the inner layer has a glass transition temperature of greater than 100° C.
  • 3. The elongate, flexible catheter of claim 1 wherein the polyamide or copolyamide of the outer layer has a glass transition temperature of less than 55° C.
  • 4. The elongate, flexible catheter of claim 1 wherein the amorphous polyamide of the inner layer and the polyamide or copolyamide of the outer layer have a common amide block.
  • 5. The elongate, flexible catheter of claim 4 wherein the common amide block is selected from a group comprising nylon 12, nylon 11, nylon 6, and nylon 6,6.
  • 6. The elongate, flexible catheter of claim 1 wherein the inner polyamide includes a cycloaliphatic segment.
  • 7. The elongate, flexible catheter of claim 1 wherein the inner polyamide includes an aliphatic segment.
  • 8. The elongate, flexible catheter of claim 1 wherein the inner polyamide includes an aromatic segment.
  • 9. The elongate, flexible catheter of claim 1 wherein the inner polyamide comprises at least two segments of a group including aliphatic segments, aromatic segments, and cycloaliphatic segments.
  • 10. The elongate, flexible catheter shaft of claim 1 wherein the inner and outer layers are formed by co-extrusion.
  • 11. The elongate, flexible catheter shaft of claim 10 wherein the catheter shaft is tapered.
  • 12. The elongate, flexible catheter shaft of claim 10 wherein the catheter shaft has a necked diameter portion.
  • 13. The elongate, flexible catheter shaft of claim 1 wherein the outer layer is a polymer of nylon or a block copolymer of nylon.
  • 14. The elongate, flexible catheter shaft of claim 13 wherein the nylon is nylon 11, nylon 12, nylon 6, nylon 6,6 or nylon 6,12.
  • 15. The elongate, flexible catheter shaft of claim 13 wherein the block copolymer is a block copolymer of nylon and polytetramethylene oxide.
  • 16. The elongate, flexible catheter shaft of claim 15 wherein the nylon is nylon 11, nylon 12, nylon 6, nylon 6,6 or nylon 6,12.
  • 17. The elongate, flexible catheter of claim 1 wherein the outer layer comprises a block copolymer of nylon 12 and polytetramethylene oxide.
  • 18. The elongate, flexible catheter of claim 1 wherein the shaft has an enhanced resistance to solvents as compared to a similar shaft of a single layer of the amorphous polyamide having a Shore D durometer value of greater than 78.
  • 19. The elongate, flexible catheter of claim 1 wherein the outer layer is thinner than the inner layer along substantially an entire length of the shaft extending from the proximal end to the distal end.
  • 20. An elongate, flexible catheter, comprising: a shaft having a proximal end, a distal end, and a lumen extending therein, the shaft having an inner layer comprising high density polyethylene and an outer layer comprising a blend of two polymers, including a first polymer being an amorphous nylon having a Shore D durometer value of greater than 78 and a second polymer having a Shore D durometer value of no more than 76, wherein the inner layer is thicker than the outer layer, the shaft having an increased resistance to kinking as compared to a similar shaft having an inner layer of the high density polyethylene and an outer layer of the amorphous nylon having a Shore D durometer value of greater than 78.
  • 21. The elongate, flexible catheter of claim 20 further comprising an intermediate layer disposed between the inner layer and the outer layer, the intermediate layer serving as a bonding layer.
  • 22. The elongate, flexible catheter of claim 20 wherein the first polymer and the second polymer have a common amide block.
  • 23. The elongate, flexible catheter of claim 22 wherein the common amide block is selected from a group comprising nylon 12, nylon 11, nylon 6, and nylon 6,6.
  • 24. The elongate, flexible catheter of claim 20 wherein the first polymer includes a cycloaliphatic segment.
  • 25. The elongate, flexible catheter of claim 20 wherein the first polymer includes an aliphatic segment.
  • 26. The elongate, flexible catheter of claim 20 wherein the first polymer includes an aromatic segment.
  • 27. The elongate, flexible catheter of claim 20 wherein the first polymer comprises at least two segments of a group including aliphatic segments, aromatic segments, and cycloaliphatic segments.
  • 28. The elongate, flexible catheter of claim 20 wherein the inner layer and outer layer are formed by co-extrusion.
  • 29. The elongate, flexible catheter of claim 20 wherein the second polymer is a semi-crystalline polymer of nylon or a block copolymer of nylon.
  • 30. The elongate, flexible catheter of claim 29 wherein the nylon is nylon 11, nylon 12, nylon 6, nylon 6,6 or nylon 6,12.
  • 31. The elongate, flexible catheter of claim 20 wherein the block copolymer is a block copolymer of nylon and polytetramethylene oxide.
  • 32. The elongate, flexible catheter of claim 20 wherein the shaft has an enhanced resistance to solvents as compared to a similar shaft having an inner layer of the high density polyethylene and an outer layer of the amorphous nylon having a Shore D durometer value of greater than 78.
  • 33. The elongate, flexible catheter of claim 20 wherein the outer layer is thinner than the inner layer along substantially an entire length of the shaft extending from the proximal end to the distal end.
CROSS-REFERENCES TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 13/898,027, filed May 20, 2013, which is a continuation of U.S. patent application Ser. No. 12/478,929, filed Jun. 5, 2009, now U.S. Pat. No. 8,444,608, which is continuation-in-part of U.S. patent application Ser. No. 12/324,425 entitled “Low Compliant Catheter Tubing” filed Nov. 26, 2008, now U.S. Pat. No. 8,070,719, the contents each of which are incorporated by reference in their entirety.

US Referenced Citations (305)
Number Name Date Kind
4425919 Alston et al. Jan 1984 A
4563181 Wijayarathna et al. Jan 1986 A
4596563 Pande Jun 1986 A
4775371 Mueller, Jr. Oct 1988 A
4820349 Saab Apr 1989 A
4877031 Conway et al. Oct 1989 A
4886506 Lovgren et al. Dec 1989 A
4892519 Songer et al. Jan 1990 A
4952357 Euteneuer Aug 1990 A
4955895 Sugiyama et al. Sep 1990 A
4960410 Pinchuk Oct 1990 A
4976720 Machold et al. Dec 1990 A
4994047 Walker et al. Feb 1991 A
5047045 Arney et al. Sep 1991 A
5061273 Yock Oct 1991 A
5078702 Pomeranz Jan 1992 A
5085649 Flynn et al. Feb 1992 A
5112304 Barlow et al. May 1992 A
5156594 Keith Oct 1992 A
5176661 Evard et al. Jan 1993 A
5195969 Wang et al. Mar 1993 A
5205822 Johnson et al. Apr 1993 A
5207700 Euteneuer May 1993 A
5217434 Arney Jun 1993 A
5217482 Keith Jun 1993 A
5250059 Andreas et al. Oct 1993 A
5270086 Hamlin Dec 1993 A
5277199 DuBois et al. Jan 1994 A
5290232 Johnson et al. Mar 1994 A
5290306 Trotta et al. Mar 1994 A
5300025 Wantink Apr 1994 A
5304134 Kraus et al. Apr 1994 A
5312430 Rosenbluth et al. May 1994 A
5318032 Lonsbury et al. Jun 1994 A
5318526 Cohen Jun 1994 A
5334146 Ozasa Aug 1994 A
5342386 Trotta Aug 1994 A
5358486 Saab Oct 1994 A
5364357 Aase Nov 1994 A
5370616 Keith et al. Dec 1994 A
5378238 Peters et al. Jan 1995 A
5395336 Barclay et al. Mar 1995 A
5425712 Goodin Jun 1995 A
5447497 Sogard et al. Sep 1995 A
5451233 Yock Sep 1995 A
5454789 Burns et al. Oct 1995 A
5470315 Adams Nov 1995 A
5476477 Bums Dec 1995 A
5478320 Trotta Dec 1995 A
5484409 Atkinson et al. Jan 1996 A
5490837 Blaeser et al. Feb 1996 A
5496275 Sirhan et al. Mar 1996 A
5499980 Euteneuer Mar 1996 A
5507766 Kugo et al. Apr 1996 A
5512051 Wang et al. Apr 1996 A
5526823 Wheeler Jun 1996 A
5538510 Fontirroche et al. Jul 1996 A
5538513 Okajima Jul 1996 A
5545134 Hilaire et al. Aug 1996 A
5549552 Peters et al. Aug 1996 A
5554121 Ainsworth et al. Sep 1996 A
5556383 Wang et al. Sep 1996 A
5569195 Saab Oct 1996 A
5587125 Roychowdhury Dec 1996 A
5599326 Carter Feb 1997 A
5613979 Trotta et al. Mar 1997 A
5620649 Trotta Apr 1997 A
5622665 Wang Apr 1997 A
5632760 Sheiban et al. May 1997 A
5643209 Fugoso et al. Jul 1997 A
5658264 Samson Aug 1997 A
5690613 Verbeek Nov 1997 A
5728063 Preissman et al. Mar 1998 A
5743874 Fischell et al. Apr 1998 A
5743875 Sirhan et al. Apr 1998 A
5749849 Engelson et al. May 1998 A
5755690 Saab May 1998 A
5759173 Preissman et al. Jun 1998 A
5766151 Valley et al. Jun 1998 A
5769817 Burgmeier Jun 1998 A
5769819 Schwab et al. Jun 1998 A
5775327 Randolph et al. Jul 1998 A
5779731 Leavitt Jul 1998 A
5782811 Samson et al. Jul 1998 A
5791036 Goodin et al. Aug 1998 A
5792124 Horrigan et al. Aug 1998 A
5792144 Fischell et al. Aug 1998 A
5795325 Valley et al. Aug 1998 A
5795341 Samson Aug 1998 A
5797887 Rosen et al. Aug 1998 A
5814016 Valley et al. Sep 1998 A
5820594 Fontirroche et al. Oct 1998 A
5833657 Reinhardt et al. Nov 1998 A
5853400 Samson Dec 1998 A
5879369 Ishida Mar 1999 A
5879499 Corvi Mar 1999 A
5902290 Peacock et al. May 1999 A
5908406 Ostapchenko et al. Jun 1999 A
5911715 Berg et al. Jun 1999 A
5916193 Stevens et al. Jun 1999 A
5947939 Mortier et al. Sep 1999 A
5964778 Fugoso et al. Oct 1999 A
5989218 Wasicek Nov 1999 A
6004289 Saab Dec 1999 A
6004339 Wijay Dec 1999 A
6010521 Lee et al. Jan 2000 A
6021340 Randolph et al. Feb 2000 A
6024693 Schock et al. Feb 2000 A
6024722 Rau et al. Feb 2000 A
6027510 Alt Feb 2000 A
6036670 Wijeratne et al. Mar 2000 A
6056719 Mickley May 2000 A
6059751 Ostapchenko et al. May 2000 A
6059770 Peacock et al. May 2000 A
6071266 Kelley Jun 2000 A
6086556 Hamilton et al. Jul 2000 A
6102890 Stivland et al. Aug 2000 A
6124007 Wang et al. Sep 2000 A
6132824 Hamlin Oct 2000 A
6136258 Wang et al. Oct 2000 A
6146356 Wang et al. Nov 2000 A
6165166 Samuelson et al. Dec 2000 A
6165195 Wilson et al. Dec 2000 A
6168588 Wilson Jan 2001 B1
6171275 Webster, Jr. et al. Jan 2001 B1
6171278 Wang et al. Jan 2001 B1
6179810 Wantink et al. Jan 2001 B1
6179856 Barbere Jan 2001 B1
6193686 Estrada et al. Feb 2001 B1
6197015 Wilson Mar 2001 B1
6210396 MacDonald et al. Apr 2001 B1
6217547 Lee Apr 2001 B1
6217565 Cohen Apr 2001 B1
6242063 Ferrera et al. Jun 2001 B1
6245053 Benjamin Jun 2001 B1
6251093 Valley et al. Jun 2001 B1
6264683 Stack et al. Jul 2001 B1
6265016 Hostettler et al. Jul 2001 B1
6306097 Park et al. Oct 2001 B1
6306124 Jones et al. Oct 2001 B1
6308342 Qi et al. Oct 2001 B1
6358227 Ferrera et al. Mar 2002 B1
6364894 Healy et al. Apr 2002 B1
6402720 Miller et al. Jun 2002 B1
6416494 Wilkins Jul 2002 B1
6482348 Wang Nov 2002 B1
6495090 Wilkins et al. Dec 2002 B1
6495127 Wallace et al. Dec 2002 B1
6500148 Pinchuk et al. Dec 2002 B1
6508784 Shu Jan 2003 B1
6530938 Lee et al. Mar 2003 B1
6548010 Stivland et al. Apr 2003 B1
6575934 Duchamp Jun 2003 B2
6575958 Happ et al. Jun 2003 B1
6579259 Stevens et al. Jun 2003 B2
6585687 Shkolnik Jul 2003 B1
6585688 Ferrera et al. Jul 2003 B2
6589207 El-Nounou Jul 2003 B1
6589226 Owens Jul 2003 B1
6591472 Noone et al. Jul 2003 B1
6620127 Lee et al. Sep 2003 B2
6620128 Simhambhatla Sep 2003 B1
6626889 Simpson et al. Sep 2003 B1
6629961 Israelsson et al. Oct 2003 B1
6645422 Jung, Jr. et al. Nov 2003 B2
6648854 Patterson et al. Nov 2003 B1
6663614 Carter et al. Dec 2003 B1
6673291 Field et al. Jan 2004 B1
6673302 Wang et al. Jan 2004 B2
6695809 Lee Feb 2004 B1
6702802 Hancock et al. Mar 2004 B1
6718211 Smits et al. Apr 2004 B2
6733487 Keith et al. May 2004 B2
6756094 Wang et al. Jun 2004 B1
6777644 Peacock et al. Aug 2004 B2
6793647 Cryer Sep 2004 B1
6796958 Chen et al. Sep 2004 B2
6796960 Cioanta et al. Sep 2004 B2
6835189 Musbach et al. Dec 2004 B2
6837890 Chiudzinski Jan 2005 B1
6863678 Lee et al. Mar 2005 B2
6875197 Simhambhatia et al. Apr 2005 B1
6887219 Wantink et al. May 2005 B2
6890395 Simhambhatia May 2005 B2
6893456 Lumauig May 2005 B2
6911038 Mertens et al. Jun 2005 B2
6913600 Valley et al. Jul 2005 B2
6918920 Wang et al. Jul 2005 B1
6946092 Bertolino et al. Sep 2005 B1
6951555 Suresh Oct 2005 B1
6951675 Chin et al. Oct 2005 B2
6979342 Lee et al. Dec 2005 B2
7026026 Ferrera et al. Apr 2006 B2
7029732 Wang et al. Apr 2006 B2
7037291 Lee et al. May 2006 B2
7037295 Tiernan et al. May 2006 B2
7074206 Lee et al. Jul 2006 B2
7108877 Blair et al. Sep 2006 B2
7112357 Miller et al. Sep 2006 B2
7141059 Duchamp et al. Nov 2006 B2
7147817 Lim et al. Dec 2006 B1
7163523 Devens, Jr. et al. Jan 2007 B2
7195638 Sridharan Mar 2007 B1
7273485 Simpson et al. Sep 2007 B2
7335185 Tang et al. Feb 2008 B2
7341571 Harris et al. Mar 2008 B1
7556634 Lee et al. Jul 2009 B2
7662130 Lee et al. Feb 2010 B2
7828766 Durcan Nov 2010 B2
7833193 Lee et al. Nov 2010 B2
7906066 Wilson et al. Mar 2011 B2
7947059 Chin et al. May 2011 B2
8012300 Simpson et al. Sep 2011 B2
8052638 Lee et al. Nov 2011 B2
8070719 Lee et al. Dec 2011 B2
8382738 Simpson et al. Feb 2013 B2
8388602 Simpson et al. Mar 2013 B2
8403885 Arana et al. Mar 2013 B2
8444608 Haslinger et al. May 2013 B2
8613722 Lee et al. Dec 2013 B2
8657782 Arana et al. Feb 2014 B2
8721624 Wilson et al. May 2014 B2
9023174 Simpson et al. May 2015 B2
9056190 Simpson et al. Jun 2015 B2
9205223 Wilson et al. Dec 2015 B2
9216274 Arana et al. Dec 2015 B2
9381325 Haslinger et al. Jul 2016 B2
20010001812 Valley et al. May 2001 A1
20010016702 Benjamin Aug 2001 A1
20010029362 Sirhan et al. Oct 2001 A1
20010037085 Keith et al. Nov 2001 A1
20020018866 Lee et al. Feb 2002 A1
20020072755 Bigus et al. Jun 2002 A1
20020082637 Lumauig Jun 2002 A1
20020165523 Chin et al. Nov 2002 A1
20030009151 Wang Jan 2003 A1
20030028234 Miller et al. Feb 2003 A1
20030032920 Wantink Feb 2003 A1
20030055447 Lee et al. Mar 2003 A1
20030064130 Blair et al. Apr 2003 A1
20030105426 Jorgensen Jun 2003 A1
20030125712 Zhou Jul 2003 A1
20030139762 Lee Jul 2003 A1
20040059291 McDonnell et al. Mar 2004 A1
20040059292 Hisamatsu et al. Mar 2004 A1
20040064130 Carter Apr 2004 A1
20040068240 Goodin et al. Apr 2004 A1
20040087901 Rice et al. May 2004 A1
20040097892 Evans et al. May 2004 A1
20040131808 Schoenie et al. Jul 2004 A1
20040167441 Reynolds et al. Aug 2004 A1
20040170782 Wang et al. Sep 2004 A1
20040173935 Lim et al. Sep 2004 A1
20040181206 Chiu et al. Sep 2004 A1
20040191443 Hamlin Sep 2004 A1
20040215141 Clarke et al. Oct 2004 A1
20040267195 Currlin Dec 2004 A1
20040267280 Nishide et al. Dec 2004 A1
20050015048 Chiu et al. Jan 2005 A1
20050043679 Devens et al. Feb 2005 A1
20050124976 Devens et al. Jun 2005 A1
20050131445 Holman et al. Jun 2005 A1
20050148997 Valley et al. Jul 2005 A1
20050154414 Perreault et al. Jul 2005 A1
20050186370 Hamilton et al. Aug 2005 A1
20050228429 Burgmeier et al. Oct 2005 A1
20050238833 Wang et al. Oct 2005 A1
20050277878 Lee Dec 2005 A1
20060008606 Horn et al. Jan 2006 A1
20060136032 Legarda et al. Jun 2006 A1
20060165926 Weber Jul 2006 A1
20060175739 Hession et al. Aug 2006 A1
20060282041 Melsheimer et al. Dec 2006 A1
20070060863 Goeken et al. Mar 2007 A1
20070142771 Durcan Jun 2007 A1
20070167973 Stupecky et al. Jul 2007 A1
20070191813 Chen Aug 2007 A1
20070240817 Strong et al. Oct 2007 A1
20070260177 Warnack Nov 2007 A1
20070276426 Euteneuer Nov 2007 A1
20080015540 Muni et al. Jan 2008 A1
20080045895 Simpson et al. Feb 2008 A1
20080045928 Simpson et al. Feb 2008 A1
20080065188 Pallazza Mar 2008 A1
20080077085 Eidenschink et al. Mar 2008 A1
20080221550 Lee Sep 2008 A1
20080262470 Lee et al. Oct 2008 A1
20090005754 Soetermans Jan 2009 A1
20090156998 Arana et al. Jun 2009 A1
20090247946 Lee et al. Oct 2009 A1
20090264822 Johnson Oct 2009 A1
20100010439 Burgmeier et al. Jan 2010 A1
20100130925 Haslinger et al. May 2010 A1
20110315301 Simpson et al. Dec 2011 A1
20120065586 Lee et al. Mar 2012 A1
20120143129 Simpson et al. Jun 2012 A1
20120296273 Arana et al. Nov 2012 A1
20130160932 Simpson et al. Jun 2013 A1
20130178795 Wilson et al. Jul 2013 A1
20130253425 Haslinger et al. Sep 2013 A1
20140081310 Lee et al. Mar 2014 A1
20140163466 Arana et al. Jun 2014 A1
20140213967 Wilson et al. Jul 2014 A1
20150238737 Simpson et al. Aug 2015 A1
20160074636 Arana et al. Mar 2016 A1
Foreign Referenced Citations (32)
Number Date Country
0 277 368 Aug 1988 EP
0 414 350 Feb 1991 EP
0 420 488 Mar 1991 EP
0 737 487 Oct 1996 EP
0 821 979 Feb 1998 EP
0 904 795 Mar 1999 EP
0 931 558 Jul 1999 EP
0 962 227 Dec 1999 EP
1 103 280 May 2001 EP
1 287 846 Mar 2003 EP
10-290837 Nov 1998 JP
2001-018290 Jan 2001 JP
2001-353225 Dec 2001 JP
2005-167638 Jun 2005 JP
WO 8902763 Apr 1989 WO
WO 9320882 Oct 1993 WO
WO 9518647 Jul 1995 WO
WO 9603175 Feb 1996 WO
WO 9634646 Nov 1996 WO
WO 9726027 Jul 1997 WO
WO 9913924 Mar 1999 WO
WO 0134240 May 2001 WO
WO 0151115 Jul 2001 WO
WO 0189621 Nov 2001 WO
WO 0236194 May 2002 WO
WO 0236196 May 2002 WO
WO 03004248 Jan 2003 WO
WO 2005021083 Mar 2005 WO
WO 2006126311 Nov 2006 WO
WO 2007054364 May 2007 WO
WO 2007146572 Dec 2007 WO
WO 2010141765 Dec 2010 WO
Non-Patent Literature Citations (200)
Entry
U.S. Appl. No. 09/957,526, Jun. 6, 2006 Certificate of Correction.
U.S. Appl. No. 09/957,526, Jan. 24, 2005 Issue Fee payment.
U.S. Appl. No. 09/957,526, Nov. 4, 2004 Notice of Allowance.
U.S. Appl. No. 09/957,526, Sep. 21, 2004 Response to Non-Final Office Action.
U.S. Appl. No. 09/957,526, Jul. 1, 2004 Non-Final Office Action.
U.S. Appl. No. 09/957,526, Apr. 22, 2004 Amendment and Request for Continued Examination (RCE).
U.S. Appl. No. 09/957,526, Feb. 17, 2004 Final Office Action.
U.S. Appl. No. 09/957,526, Nov. 26, 2003 Response to Non-Final Office Action.
U.S. Appl. No. 09/957,526, Jun. 23, 2003 Non-Final Office Action.
U.S. Appl. No. 10/010,212, Mar. 6, 2006 Issue Fee payment.
U.S. Appl. No. 10/010,212, Feb. 9, 2006 Notice of Allowance.
U.S. Appl. No. 10/010,212, Dec. 27, 2005 Response to Final Office Action.
U.S. Appl. No. 10/010,212, Oct. 19, 2005 Final Office Action.
U.S. Appl. No. 10/010,212, Aug. 4, 2005 Response to Non-Final Office Action.
U.S. Appl. No. 10/010,212, May 6, 2005 Non-Final Office Action.
U.S. Appl. No. 10/010,212, Feb. 4, 2005 Amendment and Request for Continued Examination (RCE).
U.S. Appl. No. 10/010,212, Dec. 2, 2004 Final Office Action.
U.S. Appl. No. 10/010,212, Aug. 9, 2004 Response to Non-Final Office Action.
U.S. Appl. No. 10/010,212, Jun. 16, 2004 Non-Final Office Action.
U.S. Appl. No. 10/010,212, Mar. 22, 2004 Response to Non-Final Office Action.
U.S. Appl. No. 10/010,212, Dec. 31, 2003 Non-Final Office Action.
U.S. Appl. No. 10/010,212, Oct. 14, 2003 Amendment and Request for Continued Examination (RCE).
U.S. Appl. No. 10/010,212, Jul. 7, 2003 Final Office Action.
U.S. Appl. No. 10/010,212, Apr. 18, 2003 Response to Non-Final Office Action.
U.S. Appl. No. 10/010,212, Jan. 15, 2003 Non-Final Office Action.
U.S. Appl. No. 10/010,212, Dec. 17, 2002 Response to Restriction Requirement.
U.S. Appl. No. 10/010,212, Nov. 25, 2002 Restriction Requirement.
U.S. Appl. No. 10/392,697, Aug. 22, 2007 Issue Fee payment.
U.S. Appl. No. 10/392,697, May 31, 2007 Notice of Allowance.
U.S. Appl. No. 10/392,697, Feb. 26, 2007 Amendment and Request for Continued Examination (RCE).
U.S. Appl. No. 10/392,697, Jan. 5, 2007 Final Office Action.
U.S. Appl. No. 10/392,697, Sep. 29, 2006 Response to Non-Final Office Action.
U.S. Appl. No. 10/392,697, Jul. 13, 2006 Non-Final Office Action.
U.S. Appl. No. 10/392,697, May 1, 2006 Response to Restriction Requirement.
U.S. Appl. No. 10/392,697, Mar. 27, 2006 Restriction Requirement.
U.S. Appl. No. 11/038,971, May 29, 2009 Issue Fee payment.
U.S. Appl. No. 11/038,971, Mar. 13, 2009 Notice of Allowance.
U.S. Appl. No. 11/038,971, Sep. 19, 2008 Response to Non-Final Office Action.
U.S. Appl. No. 11/038,971, Jul. 29, 2008 Non-Final Office Action.
U.S. Appl. No. 11/038,971, Feb. 28, 2008 Response to Non-Final Office Action.
U.S. Appl. No. 11/038,971, Nov. 28, 2007 Non-Final Office Action.
U.S. Appl. No. 11/038,971, Sep. 18, 2007 Response to Non-Final Office Action.
U.S. Appl. No. 11/038,971, Jun. 28, 2007 Non-Final Office Action.
U.S. Appl. No. 11/038,971, Apr. 12, 2007 Amendment and Request for Continued Examination (RCE).
U.S. Appl. No. 11/038,971, Feb. 16, 2007 Final Office Action.
U.S. Appl. No. 11/038971, Nov. 13, 2006 Response to Non-Final Office Action.
U.S. Appl. No. 11/038,971, Sep. 21, 2006 Non-Final Office Action.
U.S. Appl. No. 11/196,134, Dec. 29, 2009 Issue Fee payment.
U.S. Appl. No. 11/196,134, Sep. 30, 2009 Notice of Allowance.
U.S. Appl. No. 11/196,134, Sep. 10, 2009 Amendment and Request for Continued Examination (RCE).
U.S. Appl. No. 11/196,134, Jun. 10, 2009 Final Office Action.
U.S. Appl. No. 11/196,134, Mar. 24, 2009 Response to Non-Final Office Action.
U.S. Appl. No. 11/196,134, Dec. 24, 2008 Non-Final Office Action.
U.S. Appl. No. 11/480,143, Feb. 3, 2011 Issue Fee payment.
U.S. Appl. No. 11/480,143, Nov. 18, 2010 Notice of Allowance.
U.S. Appl. No. 11/480,143, Aug. 23, 2010 Response to Non-Final Office Action.
U.S. Appl. No. 11/480,143, Apr. 22, 2010 Non-Final Office Action.
U.S. Appl. No. 11/480,143, Feb. 18, 2010 Amendment and Request for Continued Examination (RCE).
U.S. Appl. No. 11/480,143, Feb. 4, 2010 Advisory Action.
U.S. Appl. No. 11/480,143, Jan. 15, 2010 Response to Final Office Action.
U.S. Appl. No. 11/480,143, Aug. 18, 2009 Final Office Action.
U.S. Appl. No. 11/480,143, May 27, 2009 Response to Non-Final Office Action.
U.S. Appl. No. 11/480,143, Jan. 27, 2009 Non-Final Office Action.
U.S. Appl. No. 11/480,143, Oct. 28, 2008 Response to Restriction Requirement.
U.S. Appl. No. 11/480,143, Oct. 17, 2008 Restriction Requirement.
U.S. Appl. No. 11/763,623, Jan. 29, 2013 Issue Fee payment.
U.S. Appl. No. 11/763,623, Oct. 29, 2012 Notice of Allowance.
U.S. Appl. No. 11/763,623, Oct. 17, 2012 Applicant Initiated Interview Summary.
U.S. Appl. No. 11/763,623, Oct. 21, 2010 Examiner Interview Summary.
U.S. Appl. No. 11/763,623, Aug. 24, 2010 Amendment and Request for Continued Examination (RCE).
U.S. Appl. No. 11/763,623, May 24, 2010 Notice of Appeal.
U.S. Appl. No. 11/763,623, Feb. 23, 2010 Final Office Action.
U.S. Appl. No. 11/763,623, Jan. 15, 2010 Response to Non-Final Office Action.
U.S. Appl. No. 11/763,623, Oct. 15, 2009 Non-Final Office Action.
U.S. Appl. No. 11/763,623, Jul. 20, 2009 Amendment and Request for Continued Examination (RCE).
U.S. Appl. No. 11/763,623, Mar. 20, 2009 Final Office Action.
U.S. Appl. No. 11/763,623, Mar. 3, 2009 Response to Non-Final Office Action.
U.S. Appl. No. 11/763,623, Dec. 3, 2008 Non-Final Office Action.
U.S. Appl. No. 11/763,623, Oct. 2, 2008 Response to Restriction Requirement.
U.S. Appl. No. 11/763,623, Sep. 25, 2008 Restriction Requirement.
U.S. Appl. No. 11/844,117, Aug. 2, 2011 Issue Fee payment.
U.S. Appl. No. 11/844,117, Jun. 15, 2011 Notice of Allowance.
U.S. Appl. No. 11/844,117, Mar. 23, 2011 Response to Non-Final Office Action.
U.S. Appl. No. 11/844,117, Nov. 23, 2010 Non-Final Office Action.
U.S. Appl. No. 11/844,117, Nov. 17, 2010 Amendment and Request for Continued Examination (RCE).
U.S. Appl. No. 11/844,117, Aug. 17, 2010 Final Office Action.
U.S. Appl. No. 11/844,117, Jun. 30, 2010 Response to Notice of Non-Compliant.
U.S. Appl. No. 11/844,117, Jun. 23, 2010 Notice of Non-Compliant.
U.S. Appl. No. 11/844,117, Jun. 17, 2010 Response to Non-Final Office Action.
U.S. Appl. No. 11/844,117, Mar. 17, 2010 Non-Final Office Action.
U.S. Appl. No. 11/844,117, Jan. 5, 2010 Response to Restriction Requirement.
U.S. Appl. No. 11/844,117, Oct. 13, 2009 Restriction Requirement.
U.S. Appl. No. 11/958,106, May 21, 2013 Certificate of Correction.
U.S. Appl. No. 11/958,106, Feb. 20, 2013 Issue Fee payment.
U.S. Appl. No. 11/958,106, Nov. 20, 2012 Notice of Allowance.
U.S. Appl. No. 11/958,106, Oct. 23, 2012 Response to Non-Final Office Action.
U.S. Appl. No. 11/958,106, Aug. 1, 2012 Non-Final Office Action.
U.S. Appl. No. 11/958,106, May 29, 2012 Response to Notice of Non-Compliant.
U.S. Appl. No. 11/958,106, May 17, 2012 Notice of non-Compliant.
U.S. Appl. No. 11/958,106, May 7, 2012 Response to Non-Final Office Action.
U.S. Appl. No. 11/958,106, Jan. 6, 2012 Non-Final Office Action.
U.S. Appl. No. 11/958,106, Jun. 17, 2010 Amendment and Request for Continued Examination (RCE).
U.S. Appl. No. 11/958,106, Mar. 17, 2010 Final Office Action.
U.S. Appl. No. 11/958,106, Jan. 8, 2010 Response to Non-Final Office Action.
U.S. Appl. No. 11/958,106, Jul. 8, 2009 Non-Final Office Action.
U.S. Appl. No. 12/324,425, Oct. 31, 2011 Amendment after Notice of Allowance.
U.S. Appl. No. 12/324,425, Sep. 22, 2011 Issue Fee payment.
U.S. Appl. No. 12/324,425, Aug. 31, 2011 Notice of Allowance.
U.S. Appl. No. 12/324,425, Jun. 6, 2011 Response to Non-Final Office Action.
U.S. Appl. No. 12/324,425, Mar. 4, 2011 Non-Final Office Action.
U.S. Appl. No. 12/477,695, Jun. 21, 2016 Amendment and Request for Continued Examination (RCE).
U.S. Appl. No. 12/477,695, Apr. 21, 2016 Response after Final Office Action.
U.S. Appl. No. 12/477,695, Jan. 21, 2016 Final Office Action.
U.S. Appl. No. 12/477,695, May 16, 2014 Amendment and Request for Continued Examination (RCE).
U.S. Appl. No. 12/477,695, Jul. 1, 2015 Non-Final Office Action.
U.S. Appl. No. 12/477,695, Oct. 1, 2015 Response to Non-Final Office Action.
U.S. Appl. No. 12/477,695, Jan. 16, 2014 Final Office Action.
U.S. Appl. No. 12/477,695, Mar. 17, 2014 Response after Final Action.
U.S. Appl. No. 12/477,695, Apr. 10, 2014 Applicant Initiated Interview Summary.
U.S. Appl. No. 12/477,695, Sep. 20, 2013 Response to Non-Final Office Action.
U.S. Appl. No. 12/477,695, Jun. 20, 2013 Non-Final Office Action.
U.S. Appl. No. 12/477,695, Jan. 15, 2013 Amendment and Request for Continued Examination (RCE).
U.S. Appl. No. 12/477,695, Oct. 24, 2012 Advisory Action.
U.S. Appl. No. 12/477,695, Oct. 11, 2012 Response to Final Office Action.
U.S. Appl. No. 12/477,695, Aug. 15, 2012 Final Office Action.
U.S. Appl. No. 12/477,695, Apr. 16, 2012 Response to Non-Final Office Action.
U.S. Appl. No. 12/477,695, Dec. 16, 2011 Non-Final Office Action.
U.S. Appl. No. 12/478,929, Apr. 18, 2013 Issue Fee Payment.
U.S. Appl. No. 12/478,929, Jan. 18, 2013 Notice of Allowance.
U.S. Appl. No. 12/478,929, Sep. 24, 2012 Response to Non-Final Office Action.
U.S. Appl. No. 12/478,929, Jun. 22, 2012 Non-Final Office Action.
U.S. Appl. No. 12/478,929, Jul. 18, 2011 Request for Continued Examination (RCE).
U.S. Appl. No. 12/478,929, Jun. 6, 2011 Response after Final Office Action.
U.S. Appl. No. 12/478,929, Mar. 4, 2011 Final Office Action.
U.S. Appl. No. 12/478,929, Dec. 9, 2010 Response to Non-Final Office Action.
U.S. Appl. No. 12/478,929, Jul. 9, 2010 Non-Final Office Action.
U.S. Appl. No. 12/479,700, Sep. 22, 2011 Issue Fee payment.
U.S. Appl. No. 12/479,700, Aug. 22, 2011 Notice of Allowance.
U.S. Appl. No. 12/479,700, May 20, 2011 Response to Non-Final Office Action.
U.S. Appl. No. 12/479,700, May 13, 2011 Examiner Interview Summary.
U.S. Appl. No. 12/479,700, Apr. 27, 2011 Response to Non-Final Office Action.
U.S. Appl. No. 12/479,700, Oct. 27, 2010 Non-Final Office Action.
U.S. Appl. No. 12/479,700, Oct. 14, 2010 Response to Restriction Requirement.
U.S. Appl. No. 12/479,700, Oct. 4, 2010 Restriction Requirement.
U.S. Appl. No. 12/687,265, Oct. 14, 2010 Issue Fee payment.
U.S. Appl. No. 12/687,265, Aug. 5, 2010 Notice of Allowance.
U.S. Appl. No. 13/224,917, Dec. 10, 2014 Response to Non-Final Office Action.
U.S. Appl. No. 13/224,917, Mar. 2, 2015 Notice of Allowance.
U.S. Appl. No. 13/224,917, Mar. 25, 2015 Issue Fee Payment.
U.S. Appl. No. 13/224,917, Sep. 11, 2014 Non-Final Office Action.
U.S. Appl. No. 13/224,917, Dec. 13, 2013 Response to Non-Final Office Action.
U.S. Appl. No. 13/224,917, Sep. 12, 2013 Non-Final Office Action.
U.S. Appl. No. 13/224,917, Aug. 23, 2013 Amendment and Request for Continued Examination (RCE).
U.S. Appl. No. 13/224,917, May 28, 2013 Final Office Action.
U.S. Appl. No. 13/224,917, Jan. 14, 2013 Response to Non-Final Office Action.
U.S. Appl. No. 13/224,917, Oct. 12, 2012 Non-Final Office Action.
U.S. Appl. No. 13/240,453, Nov. 19, 2013 Issue Fee payment.
U.S. Appl. No. 13/240,453, Aug. 20, 2013 Notice of Allowance.
U.S. Appl. No. 13/240,453, Apr. 30, 2013 Response to Non-Final Office Action.
U.S. Appl. No. 13/240,453, Apr. 17, 2013 Applicant Initiated Interview Summary.
U.S. Appl. No. 13/240,453, Dec. 5, 2012 Non-Final Office Action.
U.S. Appl. No. 13/240,453, Nov. 1, 2012 Response to Restriction Requirement.
U.S. Appl. No. 13/240,453, Oct. 2, 2012 Restriction Requirement.
U.S. Appl. No. 13/398,178, Jan. 25, 2013 Issue Fee payment.
U.S. Appl. No. 13/398,178, Oct. 25, 2012 Notice of Allowance.
U.S. Appl. No. 13/398,178, Oct. 16, 2012 Preliminary Amendment.
U.S. Appl. No. 13/562,810, Jan. 9, 2014 Issue Fee Payment.
U.S. Appl. No. 13/562,810, Nov. 6, 2013 Notice of Allowance.
U.S. Appl. No. 13/562,810, Oct. 8, 2013 Response to Non-Final Office Action.
U.S. Appl. No. 13/562,810, Jul. 8, 2013 Non-Final Office Action.
U.S. Appl. No. 13/775,659, Jan. 26, 2015 Response to Non-Final Office Action.
U.S. Appl. No. 13/775,659, Feb. 17, 2015 Notice of Allowance.
U.S. Appl. No. 13/775,659, May 12, 2015 Issue Fee Payment.
U.S. Appl. No. 13/775,659, Oct. 24, 2014 Non-Final Office Action.
U.S. Appl. No. 13/775,699, Mar. 31, 2014 Issue Fee Payment.
U.S. Appl. No. 13/775,699, Dec. 31, 2013 Notice of Allowance.
U.S. Appl. No. 13/775,699, Oct. 28, 2013 Response to Restriction Requirement.
U.S. Appl. No. 13/775,699, Sep. 27, 2013 Restriction Requirement.
U.S. Appl. No. 13/898,027, Jun. 8, 2016 Issue Fee Payment.
U.S. Appl. No. 13/898,027, Mar. 21, 2016 Notice of Allowance.
U.S. Appl. No. 14/083,821, Aug. 18, 2016 Restriction Requirement Filed.
U.S. Appl. No. 14/180,550, Nov. 17, 2015 Issue Fee Payment.
U.S. Appl. No. 14/180,550, Apr. 13, 2015 Response to Non-Final Office Action.
U.S. Appl. No. 14/180,550, Aug. 17, 2015 Notice of Allowance.
U.S. Appl. No. 14/180,550, Jan. 13, 2015 Non-Final Office Action.
U.S. Appl. No. 14/230,581, Nov. 5, 2015 Issue Fee Payment.
U.S. Appl. No. 14/230,581, Aug. 5, 2015 Notice of Allowance.
U.S. Appl. No. 14/950,414, Sep. 14, 2016 Issue Fee Payment.
U.S. Appl. No. 14/950,414, Jun. 15, 2016 Notice of Allowance.
U.S. Appl. No. 14/950,414, May 6, 2016 Response to Non-Final Office Action.
U.S. Appl. No. 14/950,414, Feb. 8, 2016 Non-Final Office Action.
Cordis' Product Brochure; The Journey Inspires the Design, AQUA T3, Dec. 2002.
The Manufacturing Process Section of the Phelps Dodge High Performance Conductors Brochure, a Primer on Polymide Tubing, p. 1.
http://www.zeusinc.com/peek—resin.asp.
www.sigmaaldrich.com/img/assets/3900/Thermal—Transitions—of—Homopolymers.pdf.
Etherington & Roberts Dictionary, http://Palimpsest.stanford.edu/don/dt/dt1549.html.
Polymers: Structure and Properties, C.A. Daniels, Ph.D., P.E.; Technomic Publishing Co., Inc.
International Search Report for PCT/US2010/037313, dated Apr. 28, 2011.
International Search Report for PCT/US2007/071873, dated Apr. 14, 2008.
International Search Report for PCT/US2008/086270, dated Jun. 3, 2009.
Related Publications (1)
Number Date Country
20160279300 A1 Sep 2016 US
Continuations (2)
Number Date Country
Parent 13898027 May 2013 US
Child 15176297 US
Parent 12478929 Jun 2009 US
Child 13898027 US
Continuation in Parts (1)
Number Date Country
Parent 12324425 Nov 2008 US
Child 12478929 US